HAYWARD,
Calif., Aug. 10, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that an abstract, entitled,
"The Impact of Sublingual Sufentanil on Postoperative Pain Control
in Patients Undergoing Spine Surgery" (abstract # A4262) was
accepted for e-Abstract presentation at the
ANESTHESIOLOGY® 2022 annual meeting, being held
October 21-25, 2022 in New Orleans, LA.
E-Abstracts will be presented virtually and made available to
registrants throughout the entire meeting from Saturday, October 22 (7:00
a.m. US Central Time) to Tuesday,
October 25, 2022 (3:00 p.m.
U.S. Central Time). The abstracts will remain available and open to
meeting attendees for three months after the meeting.
About the ANESTHESIOLOGY 2022
Annual Meeting
The ANESTHESIOLOGY Annual Meeting is the marquee annual event
for the American Society of Anesthesiologists®. Founded in 1905,
the American Society of Anesthesiologists is an educational,
research and scientific association
of physicians organized to raise the standards of the
medical practice of anesthesiology and to improve patient
care. As of 2021, the organization included more than 55,000
national and international members.
About DSUVIA (sufentanil
sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in
certified medically supervised healthcare settings, such as
hospitals, surgical centers, and emergency departments, for the
management of acute pain severe enough to require an opioid
analgesic and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile, when delivered
sublingually, avoids the high peak plasma levels and short duration
of action observed with IV administration. DZUVEO has been approved
by the European Medicines Agency and AcelRx's European
commercialization partner, Aguettant, will market the drug in
Europe.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals,
Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings.
AcelRx's proprietary, non-invasive sublingual formulation
technology delivers sufentanil with consistent pharmacokinetic
profiles. The Company has one approved product in the U.S.,
DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as
DZUVEO® in Europe,
indicated for the management of acute pain severe enough to require
an opioid analgesic for adult patients in certified medically
supervised healthcare settings, and several product candidates. The
product candidates include: Zalviso® (sufentanil
sublingual tablet system, SST system, 15 mcg), an investigational
product in the U.S. being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings; two
pre-filled, ready-to-use syringes of ephedrine and phenylephrine
licensed for the U.S. from Aguettant; Niyad™, a regional
anticoagulant for the extracorporeal circuit; and LTX-608, for the
potential treatment of COVID-19, disseminated intravascular
coagulation, acute respiratory distress syndrome and acute
pancreatitis. DZUVEO is an approved product in Europe.
This release is intended for investors only. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-abstract-acceptance-for-podium-presentation-at-the-anesthesiology-2022-annual-meeting-301603228.html
SOURCE AcelRx Pharmaceuticals, Inc.